GENOVAC announces antibody discovery collaboration with ESBATech

30-Sep-2010 - Germany
GENOVAC GmbH announced that they have entered into a research collaboration with ESBATech, an Alcon Biomedical Research Unit relative to the generation of antibodies for use in the field of ophthalmology. Under the terms of the agreement, GENOVAC will apply its proprietary genetic immunisation technology to generate high affinity antibodies against molecular targets identified by ESBATech. ESBATech further develops these antibodies towards therapeutic antibody fragments by applying its proprietary platform technologies. The results obtained with the first projects showed the superior quality of the resulting antibodies and the high potential for future projects. "Our alliance with ESBATech is another proof for the technological superiority of genetic immunisation and we are proud to help ESBATech to develop new antibody therapies in the future," commented Dr John Thompson, Managing Director of GENOVAC.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous